Subcutaneous Benlysta belimumab regulatory update

GlaxoSmithKline submitted a BLA to FDA and a regulatory application to EMA for subcutaneous Benlysta belimumab to treat adults with active, autoantibody-positive systemic lupus erythematosus (SLE). Th...